Compare Sana Biotechnology Inc (SANA) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $73.32. The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | VEA | |
|---|---|---|
Market Cap | $1.13B | — |
Sector | Health | — |
52-Week High | $5.92 | $73.30 |
52-Week Low | $2.68 | $58.19 |
Enterprise Value | $1.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
VEA trades at $73.30, up 1.1% with a bullish technical signal from moving averages. The ETF shows mixed institutional activity with recent buying from Ferguson Shapiro and selling from Financial Advisory Corp. Technical indicators show overbought RSI conditions while maintaining strong momentum with ADX at 47.42. The fund offers international diversification with a low expense ratio of 0.03% and upcoming dividend payment.
VEA presents a compelling international diversification opportunity with strong technical momentum and cost efficiency. However, overbought conditions and mixed institutional sentiment suggest potential near-term volatility. The fund's focus on developed markets outside the US provides geographic diversification but remains exposed to global economic headwinds and currency fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
